Accolade, Inc. (NASDAQ: ACCD) Stock Competitors & Peer Comparison
See ACCD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ACCD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACCD | $7.02 | +0.00% | 575.6M | -3.08 | -$2.28 | N/A |
| VEEV | $189.24 | -4.14% | 30.7B | 22.71 | $8.33 | N/A |
| GEHC | $62.04 | -1.26% | 28.2B | 13.61 | $4.56 | +0.23% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSGU | $239.04 | +3.24% | 14.4B | 216.59 | $1.11 | N/A |
| BTSG | $72.56 | +2.92% | 14.2B | 58.52 | $1.24 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| TEM | $48.98 | +1.18% | 8.5B | -97.96 | -$0.50 | N/A |
| HQY | $97.77 | -1.12% | 8.2B | 22.84 | $4.28 | N/A |
| HNGE | $84.35 | -3.82% | 6.5B | 43.22 | $1.95 | N/A |
Stock Comparison
Veeva Systems Inc. (NYSE: VEEV)
ACCD vs VEEV Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, VEEV has a market cap of 30.7B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while VEEV trades at $189.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas VEEV's P/E ratio is 22.71. In terms of profitability, ACCD's ROE is -0.22%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, ACCD is less volatile compared to VEEV. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check VEEV's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
ACCD vs GEHC Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, GEHC has a market cap of 28.2B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while GEHC trades at $62.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas GEHC's P/E ratio is 13.61. In terms of profitability, ACCD's ROE is -0.22%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ACCD is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check GEHC's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHCV)
ACCD vs GEHCV Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas GEHCV's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, ACCD is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check GEHCV's competition here
BrightSpring Health Services, Inc. Tangible Equity Unit (NASDAQ: BTSGU)
ACCD vs BTSGU Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BTSGU has a market cap of 14.4B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BTSGU trades at $239.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BTSGU's P/E ratio is 216.59. In terms of profitability, ACCD's ROE is -0.22%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to BTSGU. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check BTSGU's competition here
BrightSpring Health Services, Inc. Common Stock (NASDAQ: BTSG)
ACCD vs BTSG Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BTSG has a market cap of 14.2B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BTSG trades at $72.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BTSG's P/E ratio is 58.52. In terms of profitability, ACCD's ROE is -0.22%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to BTSG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check BTSG's competition here
Signify Health, Inc. (NYSE: SGFY)
ACCD vs SGFY Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SGFY's P/E ratio is 70.91. In terms of profitability, ACCD's ROE is -0.22%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, ACCD is less volatile compared to SGFY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SGFY's competition here
Tempus AI, Inc. (NASDAQ: TEM)
ACCD vs TEM Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TEM has a market cap of 8.5B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TEM trades at $48.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TEM's P/E ratio is -97.96. In terms of profitability, ACCD's ROE is -0.22%, compared to TEM's ROE of -0.70%. Regarding short-term risk, ACCD is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TEM's competition here
HealthEquity, Inc. (NASDAQ: HQY)
ACCD vs HQY Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HQY has a market cap of 8.2B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HQY trades at $97.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HQY's P/E ratio is 22.84. In terms of profitability, ACCD's ROE is -0.22%, compared to HQY's ROE of +0.11%. Regarding short-term risk, ACCD is less volatile compared to HQY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HQY's competition here
Hinge Health, Inc. (NYSE: HNGE)
ACCD vs HNGE Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HNGE has a market cap of 6.5B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HNGE trades at $84.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HNGE's P/E ratio is 43.22. In terms of profitability, ACCD's ROE is -0.22%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, ACCD is less volatile compared to HNGE. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HNGE's competition here
R1 RCM Inc. (NASDAQ: RCM)
ACCD vs RCM Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas RCM's P/E ratio is -102.21. In terms of profitability, ACCD's ROE is -0.22%, compared to RCM's ROE of +0.00%. Regarding short-term risk, ACCD is similarly volatile compared to RCM. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check RCM's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ACCD vs TXG Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TXG has a market cap of 6B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TXG trades at $47.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TXG's P/E ratio is -277.65. In terms of profitability, ACCD's ROE is -0.22%, compared to TXG's ROE of -0.03%. Regarding short-term risk, ACCD is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TXG's competition here
Doximity, Inc. (NYSE: DOCS)
ACCD vs DOCS Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, DOCS has a market cap of 3.9B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while DOCS trades at $21.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas DOCS's P/E ratio is 13.79. In terms of profitability, ACCD's ROE is -0.22%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, ACCD is less volatile compared to DOCS. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check DOCS's competition here
1Life Healthcare, Inc. (NASDAQ: ONEM)
ACCD vs ONEM Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ONEM's P/E ratio is -7.77. In terms of profitability, ACCD's ROE is -0.22%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, ACCD is less volatile compared to ONEM. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ONEM's competition here
Privia Health Group, Inc. (NASDAQ: PRVA)
ACCD vs PRVA Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PRVA has a market cap of 3.3B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PRVA trades at $26.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PRVA's P/E ratio is 164.44. In terms of profitability, ACCD's ROE is -0.22%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, ACCD is less volatile compared to PRVA. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PRVA's competition here
Progyny, Inc. (NASDAQ: PGNY)
ACCD vs PGNY Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PGNY has a market cap of 2.5B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PGNY trades at $32.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PGNY's P/E ratio is 23.53. In terms of profitability, ACCD's ROE is -0.22%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, ACCD is less volatile compared to PGNY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PGNY's competition here
Heartflow, Inc. Common Stock (NASDAQ: HTFL)
ACCD vs HTFL Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HTFL has a market cap of 2.2B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HTFL trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HTFL's P/E ratio is -12.66. In terms of profitability, ACCD's ROE is -0.22%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, ACCD is less volatile compared to HTFL. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HTFL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
ACCD vs WGS Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, WGS has a market cap of 1.8B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while WGS trades at $61.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas WGS's P/E ratio is 72.53. In terms of profitability, ACCD's ROE is -0.22%, compared to WGS's ROE of -0.28%. Regarding short-term risk, ACCD is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check WGS's competition here
Teladoc Health, Inc. (NYSE: TDOC)
ACCD vs TDOC Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TDOC has a market cap of 1.8B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TDOC trades at $9.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TDOC's P/E ratio is -10.79. In terms of profitability, ACCD's ROE is -0.22%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, ACCD is less volatile compared to TDOC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TDOC's competition here
NextGen Healthcare, Inc. (NASDAQ: NXGN)
ACCD vs NXGN Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas NXGN's P/E ratio is -266.00. In terms of profitability, ACCD's ROE is -0.22%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, ACCD is less volatile compared to NXGN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check NXGN's competition here
Agiliti, Inc. (NYSE: AGTI)
ACCD vs AGTI Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AGTI's P/E ratio is -71.79. In terms of profitability, ACCD's ROE is -0.22%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, ACCD is less volatile compared to AGTI. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AGTI's competition here
Omada Health (NASDAQ: OMDA)
ACCD vs OMDA Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while OMDA trades at $22.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas OMDA's P/E ratio is 328.43. In terms of profitability, ACCD's ROE is -0.22%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, ACCD is less volatile compared to OMDA. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check OMDA's competition here
Certara, Inc. (NASDAQ: CERT)
ACCD vs CERT Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CERT has a market cap of 1.1B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CERT trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CERT's P/E ratio is 17.56. In terms of profitability, ACCD's ROE is -0.22%, compared to CERT's ROE of -0.01%. Regarding short-term risk, ACCD is less volatile compared to CERT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CERT's competition here
GoodRx Holdings, Inc. (NASDAQ: GDRX)
ACCD vs GDRX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, GDRX has a market cap of 1B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while GDRX trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas GDRX's P/E ratio is 9.15. In terms of profitability, ACCD's ROE is -0.22%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, ACCD is less volatile compared to GDRX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check GDRX's competition here
CareCloud, Inc. (NASDAQ: CCLDO)
ACCD vs CCLDO Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CCLDO's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, ACCD is similarly volatile compared to CCLDO. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check CCLDO's competition here
HealthStream, Inc. (NASDAQ: HSTM)
ACCD vs HSTM Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HSTM has a market cap of 813.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HSTM trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HSTM's P/E ratio is 36.63. In terms of profitability, ACCD's ROE is -0.22%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, ACCD is less volatile compared to HSTM. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HSTM's competition here
Evolent Health, Inc. (NYSE: EVH)
ACCD vs EVH Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, EVH has a market cap of 656.9M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while EVH trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas EVH's P/E ratio is 584.00. In terms of profitability, ACCD's ROE is -0.22%, compared to EVH's ROE of -0.78%. Regarding short-term risk, ACCD is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check EVH's competition here
Phreesia, Inc. (NYSE: PHR)
ACCD vs PHR Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PHR has a market cap of 654.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PHR trades at $10.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PHR's P/E ratio is 37.82. In terms of profitability, ACCD's ROE is -0.22%, compared to PHR's ROE of +0.03%. Regarding short-term risk, ACCD is less volatile compared to PHR. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PHR's competition here
MultiPlan Corporation (NYSE: MPLN-WT)
ACCD vs MPLN-WT Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, ACCD is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MPLN-WT's competition here
Sharecare, Inc. (NASDAQ: SHCR)
ACCD vs SHCR Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SHCR's P/E ratio is -3.76. In terms of profitability, ACCD's ROE is -0.22%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, ACCD is less volatile compared to SHCR. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SHCR's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
ACCD vs WGSWW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, WGSWW has a market cap of 514.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas WGSWW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, ACCD is less volatile compared to WGSWW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check WGSWW's competition here
Claritev Corporation (NYSE: CTEV)
ACCD vs CTEV Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CTEV has a market cap of 488.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CTEV trades at $28.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CTEV's P/E ratio is -2.20. In terms of profitability, ACCD's ROE is -0.22%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, ACCD is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CTEV's competition here
NRC Health (NASDAQ: NRC)
ACCD vs NRC Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, NRC has a market cap of 484.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while NRC trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas NRC's P/E ratio is 26.20. In terms of profitability, ACCD's ROE is -0.22%, compared to NRC's ROE of +0.57%. Regarding short-term risk, ACCD is less volatile compared to NRC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check NRC's competition here
SOPHiA GENETICS S.A. (NASDAQ: SOPH)
ACCD vs SOPH Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SOPH has a market cap of 446.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SOPH trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SOPH's P/E ratio is -12.50. In terms of profitability, ACCD's ROE is -0.22%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, ACCD is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SOPH's competition here
SomaLogic, Inc. (NASDAQ: SLGCW)
ACCD vs SLGCW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, ACCD's ROE is -0.22%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, ACCD is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SLGCW's competition here
SomaLogic, Inc. (NASDAQ: SLGC)
ACCD vs SLGC Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SLGC's P/E ratio is -3.04. In terms of profitability, ACCD's ROE is -0.22%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, ACCD is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SLGC's competition here
TruBridge, Inc. (NASDAQ: TBRG)
ACCD vs TBRG Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TBRG trades at $26.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TBRG's P/E ratio is 9.37. In terms of profitability, ACCD's ROE is -0.22%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, ACCD is less volatile compared to TBRG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TBRG's competition here
MultiPlan Corporation (NYSE: MPLN)
ACCD vs MPLN Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MPLN's P/E ratio is -0.23. In terms of profitability, ACCD's ROE is -0.22%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, ACCD is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MPLN's competition here
Simulations Plus, Inc. (NASDAQ: SLP)
ACCD vs SLP Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SLP has a market cap of 368.7M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SLP trades at $18.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SLP's P/E ratio is 20.72. In terms of profitability, ACCD's ROE is -0.22%, compared to SLP's ROE of +0.06%. Regarding short-term risk, ACCD is less volatile compared to SLP. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SLP's competition here
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC)
ACCD vs TRHC Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas TRHC's P/E ratio is -4.27. In terms of profitability, ACCD's ROE is -0.22%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, ACCD is less volatile compared to TRHC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TRHC's competition here
Sema4 Holdings Corp. (NASDAQ: SMFR)
ACCD vs SMFR Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SMFR's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, ACCD is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SMFR's competition here
So-Young International Inc. (NASDAQ: SY)
ACCD vs SY Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SY has a market cap of 240.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SY trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SY's P/E ratio is -5.55. In terms of profitability, ACCD's ROE is -0.22%, compared to SY's ROE of -0.16%. Regarding short-term risk, ACCD is less volatile compared to SY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SY's competition here
Spok Holdings, Inc. (NASDAQ: SPOK)
ACCD vs SPOK Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SPOK has a market cap of 222.7M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SPOK trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SPOK's P/E ratio is 17.77. In terms of profitability, ACCD's ROE is -0.22%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, ACCD is less volatile compared to SPOK. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SPOK's competition here
American Well Corporation (NYSE: AMWL)
ACCD vs AMWL Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AMWL has a market cap of 209M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AMWL trades at $12.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AMWL's P/E ratio is -2.41. In terms of profitability, ACCD's ROE is -0.22%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, ACCD is less volatile compared to AMWL. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AMWL's competition here
Health Catalyst, Inc. (NASDAQ: HCAT)
ACCD vs HCAT Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HCAT has a market cap of 159.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HCAT trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HCAT's P/E ratio is 10.80. In terms of profitability, ACCD's ROE is -0.22%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, ACCD is less volatile compared to HCAT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HCAT's competition here
Computer Programs and Systems, Inc. (NASDAQ: CPSI)
ACCD vs CPSI Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CPSI's P/E ratio is -183.80. In terms of profitability, ACCD's ROE is -0.22%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, ACCD is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CPSI's competition here
OptimizeRx Corp. (NASDAQ: OPRX)
ACCD vs OPRX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, OPRX has a market cap of 125M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while OPRX trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas OPRX's P/E ratio is 6.11. In terms of profitability, ACCD's ROE is -0.22%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, ACCD is less volatile compared to OPRX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check OPRX's competition here
Augmedix, Inc. (NASDAQ: AUGX)
ACCD vs AUGX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AUGX's P/E ratio is -4.99. In terms of profitability, ACCD's ROE is -0.22%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, ACCD is less volatile compared to AUGX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AUGX's competition here
CareCloud, Inc. (NASDAQ: CCLD)
ACCD vs CCLD Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLD has a market cap of 94.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CCLD trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CCLD's P/E ratio is 8.26. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to CCLD. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CCLD's competition here
Definitive Healthcare Corp. (NASDAQ: DH)
ACCD vs DH Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, DH has a market cap of 76.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while DH trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas DH's P/E ratio is 2.79. In terms of profitability, ACCD's ROE is -0.22%, compared to DH's ROE of -0.67%. Regarding short-term risk, ACCD is less volatile compared to DH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check DH's competition here
Forian Inc. (NASDAQ: FORA)
ACCD vs FORA Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas FORA's P/E ratio is -24.11. In terms of profitability, ACCD's ROE is -0.22%, compared to FORA's ROE of -0.17%. Regarding short-term risk, ACCD is similarly volatile compared to FORA. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check FORA's competition here
CareCloud, Inc. (NASDAQ: CCLDP)
ACCD vs CCLDP Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CCLDP's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to CCLDP. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CCLDP's competition here
OneMedNet Corporation (NASDAQ: ONMD)
ACCD vs ONMD Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ONMD has a market cap of 37.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ONMD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ONMD's P/E ratio is -4.36. In terms of profitability, ACCD's ROE is -0.22%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, ACCD is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ONMD's competition here
Science 37 Holdings, Inc. (NASDAQ: SNCE)
ACCD vs SNCE Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SNCE's P/E ratio is -0.27. In terms of profitability, ACCD's ROE is -0.22%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, ACCD is less volatile compared to SNCE. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SNCE's competition here
Akili, Inc. (NASDAQ: AKLI)
ACCD vs AKLI Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AKLI's P/E ratio is -0.71. In terms of profitability, ACCD's ROE is -0.22%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, ACCD is less volatile compared to AKLI. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AKLI's competition here
SHL Telemedicine Ltd. (NASDAQ: SHLT)
ACCD vs SHLT Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SHLT's P/E ratio is -3.87. In terms of profitability, ACCD's ROE is -0.22%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, ACCD is similarly volatile compared to SHLT. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check SHLT's competition here
OneMedNet Corporation (NASDAQ: ONMDW)
ACCD vs ONMDW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ONMDW has a market cap of 33.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ONMDW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ONMDW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, ACCD is similarly volatile compared to ONMDW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check ONMDW's competition here
Sharecare, Inc. (NASDAQ: SHCRW)
ACCD vs SHCRW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, ACCD is less volatile compared to SHCRW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SHCRW's competition here
EUDA Health Holdings Limited (NASDAQ: EUDA)
ACCD vs EUDA Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, EUDA has a market cap of 26.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while EUDA trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas EUDA's P/E ratio is -27.08. In terms of profitability, ACCD's ROE is -0.22%, compared to EUDA's ROE of +0.70%. Regarding short-term risk, ACCD is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check EUDA's competition here
Streamline Health Solutions, Inc. (NASDAQ: STRM)
ACCD vs STRM Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas STRM's P/E ratio is -2.40. In terms of profitability, ACCD's ROE is -0.22%, compared to STRM's ROE of -0.32%. Regarding short-term risk, ACCD is similarly volatile compared to STRM. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check STRM's competition here
Renalytix Plc (NASDAQ: RNLX)
ACCD vs RNLX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas RNLX's P/E ratio is -0.33. In terms of profitability, ACCD's ROE is -0.22%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, ACCD is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check RNLX's competition here
MSP Recovery, Inc. (NASDAQ: LIFW)
ACCD vs LIFW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas LIFW's P/E ratio is -0.02. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, ACCD is similarly volatile compared to LIFW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check LIFW's competition here
HeartBeam, Inc. (NASDAQ: BEATW)
ACCD vs BEATW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BEATW has a market cap of 18M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BEATW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BEATW's P/E ratio is -0.05. In terms of profitability, ACCD's ROE is -0.22%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, ACCD is similarly volatile compared to BEATW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check BEATW's competition here
Babylon Holdings Limited (NYSE: BBLN)
ACCD vs BBLN Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BBLN's P/E ratio is -0.04. In terms of profitability, ACCD's ROE is -0.22%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, ACCD is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check BBLN's competition here
ETAO International Co., Ltd. (NASDAQ: ETAO)
ACCD vs ETAO Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ETAO's P/E ratio is -0.01. In terms of profitability, ACCD's ROE is -0.22%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, ACCD is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ETAO's competition here
Bullfrog AI Holdings, Inc. Common Stock (NASDAQ: BFRG)
ACCD vs BFRG Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, BFRG has a market cap of 7.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BFRG trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas BFRG's P/E ratio is -1.19. In terms of profitability, ACCD's ROE is -0.22%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, ACCD is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check BFRG's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
ACCD vs SCNX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SCNX has a market cap of 6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SCNX trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SCNX's P/E ratio is -0.15. In terms of profitability, ACCD's ROE is -0.22%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, ACCD is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SCNX's competition here
UpHealth, Inc. (NYSE: UPH)
ACCD vs UPH Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas UPH's P/E ratio is -0.07. In terms of profitability, ACCD's ROE is -0.22%, compared to UPH's ROE of -1.05%. Regarding short-term risk, ACCD is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check UPH's competition here
UpHealth, Inc. (NYSE: UPH-WT)
ACCD vs UPH-WT Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, ACCD is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check UPH-WT's competition here
Mangoceuticals, Inc. (NASDAQ: MGRX)
ACCD vs MGRX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MGRX has a market cap of 4.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MGRX trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MGRX's P/E ratio is -0.35. In terms of profitability, ACCD's ROE is -0.22%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, ACCD is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MGRX's competition here
Pear Therapeutics, Inc. (NASDAQ: PEAR)
ACCD vs PEAR Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PEAR's P/E ratio is -0.08. In terms of profitability, ACCD's ROE is -0.22%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PEAR's competition here
Pear Therapeutics, Inc. (NASDAQ: PEARW)
ACCD vs PEARW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas PEARW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PEARW's competition here
Ontrak, Inc. (NASDAQ: OTRK)
ACCD vs OTRK Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas OTRK's P/E ratio is -0.02. In terms of profitability, ACCD's ROE is -0.22%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, ACCD is similarly volatile compared to OTRK. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check OTRK's competition here
Healthcare Triangle, Inc. (NASDAQ: HCTI)
ACCD vs HCTI Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, HCTI has a market cap of 2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HCTI trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas HCTI's P/E ratio is -0.22. In terms of profitability, ACCD's ROE is -0.22%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, ACCD is less volatile compared to HCTI. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HCTI's competition here
CareMax, Inc. (NASDAQ: CMAX)
ACCD vs CMAX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CMAX's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, ACCD is similarly volatile compared to CMAX. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check CMAX's competition here
VSee Health, Inc. (NASDAQ: VSEE)
ACCD vs VSEE Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, VSEE has a market cap of 1.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while VSEE trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas VSEE's P/E ratio is -0.17. In terms of profitability, ACCD's ROE is -0.22%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, ACCD is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check VSEE's competition here
Aclarion, Inc. (NASDAQ: ACON)
ACCD vs ACON Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ACON has a market cap of 1.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ACON trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ACON's P/E ratio is -0.24. In terms of profitability, ACCD's ROE is -0.22%, compared to ACON's ROE of -0.54%. Regarding short-term risk, ACCD is less volatile compared to ACON. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ACON's competition here
MSP Recovery, Inc. (NASDAQ: LIFWZ)
ACCD vs LIFWZ Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, ACCD is similarly volatile compared to LIFWZ. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check LIFWZ's competition here
VSee Health, Inc. (NASDAQ: VSEEW)
ACCD vs VSEEW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, VSEEW has a market cap of 1.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while VSEEW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, ACCD's ROE is -0.22%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, ACCD is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check VSEEW's competition here
EUDA Health Holdings Limited (NASDAQ: EUDAW)
ACCD vs EUDAW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, EUDAW has a market cap of 926.3K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while EUDAW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, ACCD's ROE is -0.22%, compared to EUDAW's ROE of +0.70%. Regarding short-term risk, ACCD is similarly volatile compared to EUDAW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check EUDAW's competition here
SCWorx Corp. (NASDAQ: WORX)
ACCD vs WORX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, WORX has a market cap of 602.8K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while WORX trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas WORX's P/E ratio is -0.66. In terms of profitability, ACCD's ROE is -0.22%, compared to WORX's ROE of -0.65%. Regarding short-term risk, ACCD is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check WORX's competition here
MSP Recovery, Inc. (NASDAQ: MSPRZ)
ACCD vs MSPRZ Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, ACCD is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MSPRZ's competition here
Akerna Corp. (NASDAQ: KERNW)
ACCD vs KERNW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas KERNW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, ACCD is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check KERNW's competition here
Akerna Corp. (NASDAQ: KERN)
ACCD vs KERN Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas KERN's P/E ratio is -0.01. In terms of profitability, ACCD's ROE is -0.22%, compared to KERN's ROE of -0.17%. Regarding short-term risk, ACCD is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check KERN's competition here
MSP Recovery, Inc. (NASDAQ: LIFWW)
ACCD vs LIFWW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas LIFWW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, ACCD is similarly volatile compared to LIFWW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check LIFWW's competition here
Zhongchao Inc. (NASDAQ: ZCMD)
ACCD vs ZCMD Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ZCMD has a market cap of 51.1K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ZCMD trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ZCMD's P/E ratio is -0.05. In terms of profitability, ACCD's ROE is -0.22%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, ACCD is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ZCMD's competition here
CareMax, Inc. (NASDAQ: CMAXW)
ACCD vs CMAXW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CMAXW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, ACCD is similarly volatile compared to CMAXW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check CMAXW's competition here
Aclarion, Inc. (NASDAQ: ACONW)
ACCD vs ACONW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, ACONW has a market cap of 11.2K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ACONW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas ACONW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, ACCD is less volatile compared to ACONW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ACONW's competition here
Castlight Health, Inc. (NYSE: CSLT)
ACCD vs CSLT Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CSLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CSLT's P/E ratio is -37.27. In terms of profitability, ACCD's ROE is -0.22%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, ACCD is less volatile compared to CSLT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CSLT's competition here
Affymetrix, Inc. (NASDAQ: AFFX)
ACCD vs AFFX Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AFFX trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas AFFX's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, ACCD is less volatile compared to AFFX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AFFX's competition here
Sema4 Holdings Corp. (NASDAQ: SMFRW)
ACCD vs SMFRW Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas SMFRW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to SMFRW's ROE of -0.28%. Regarding short-term risk, ACCD is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SMFRW's competition here
Cerner Corporation (NASDAQ: CERN)
ACCD vs CERN Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CERN has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CERN's P/E ratio is 55.84. In terms of profitability, ACCD's ROE is -0.22%, compared to CERN's ROE of +0.14%. Regarding short-term risk, ACCD is less volatile compared to CERN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CERN's competition here
CareCloud, Inc. (NASDAQ: MTBCO)
ACCD vs MTBCO Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MTBCO's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to MTBCO. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MTBCO's competition here
MSP Recovery, Inc. (NASDAQ: MSPRV)
ACCD vs MSPRV Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MSPRV trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MSPRV's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MSPRV's ROE of N/A. Regarding short-term risk, ACCD is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MSPRV's competition here
CareCloud, Inc. (NASDAQ: MTBCP)
ACCD vs MTBCP Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MTBCP's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to MTBCP. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MTBCP's competition here
CareCloud, Inc. (NASDAQ: MTBC)
ACCD vs MTBC Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas MTBC's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MTBC's competition here
Change Healthcare Inc. (NASDAQ: CHNG)
ACCD vs CHNG Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CHNG's P/E ratio is -152.72. In terms of profitability, ACCD's ROE is -0.22%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, ACCD is less volatile compared to CHNG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CHNG's competition here
Convey Health Solutions Holdings, Inc. (NYSE: CNVY)
ACCD vs CNVY Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas CNVY's P/E ratio is -71.50. In terms of profitability, ACCD's ROE is -0.22%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, ACCD is less volatile compared to CNVY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CNVY's competition here
IMS Health Holdings, Inc. (NYSE: IMS)
ACCD vs IMS Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, IMS has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while IMS trades at $31.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas IMS's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to IMS's ROE of +0.27%. Regarding short-term risk, ACCD is less volatile compared to IMS. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check IMS's competition here
Alkuri Global Acquisition Corp. (NASDAQ: KURIU)
ACCD vs KURIU Comparison July 2026
Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACCD stands at 575.6M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while KURIU trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACCD currently has a P/E ratio of -3.08, whereas KURIU's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, ACCD is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check KURIU's competition here